EX937, is a first-in-class, proprietary small molecule being developed for refractory chronic cough, a large underserved market with no current FDA-approved therapies, that affects approximately 10% of the global population. Leveraging a differentiated approach by inhibiting the FAAH enzyme, EX937 has demonstrated efficacy and favorable safety in its ability to modulate chronic cough in preclinical models.
Targeting FAAH Increases the Levels of Anandamide in Lung Tissue of the Guinea Pig Chronic Cough Model1
A list of published, peer-reviewed EX937 studies, including work from international, academic research laboratories, can be found here.
For more information, please contact us.